SAAD SHAMMAS: Open Payments
NPI 1124319298 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$749 in 23 payments from 9 companies in 2025. Trend: 2023 $496 · 2024 $347 · 2025 $749
Food & beverage: $749
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $279 |
| Amgen Inc. | 5 | $174 |
| AstraZeneca Pharmaceuticals LP | 6 | $145 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Exact Sciences Corporation | 1 | $31 |
| Lilly USA, LLC | 1 | $27 |
| PFIZER INC. | 1 | $21 |
| Abbott Laboratories | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
Products named: Ozempic, REPATHA, OTEZLA, BREZTRI, AIRSUPRA, XIFAXAN, Rybelsus, Cologuard Collection Kit.
Industry payments across TX — which companies pay providers there.
